Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - eliglustat tartrate, quantity: 100 mg (equivalent: eliglustat, qty 84.4 mg) - capsule, hard - excipient ingredients: lactose monohydrate; hypromellose; microcrystalline cellulose; glycerol dibehenate; iron oxide yellow; gelatin; indigo carmine aluminium lake; titanium dioxide; mica; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - cerdelga is indicated for the long-term treatment of adult patients with gaucher disease type 1 (gd1).

Canada - English - Health Canada

sanofi genzyme, a division of sanofi-aventis canada inc - eliglustat (eliglustat tartrate) - capsule - 84mg - eliglustat (eliglustat tartrate) 84mg - other miscellaneous therapeutic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - miglustat, quantity: 100 mg - capsule, hard - excipient ingredients: magnesium stearate; povidone; sodium starch glycollate; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid; potassium hydroxide; industrial methylated spirit; ammonia; sorbitan monolaurate; gelatin; sodium lauryl sulfate - zavesca is indicated for the oral treatment of patients with mild to moderate type 1 gaucher disease, for whom enzyme replacement therapy is not a therapeutic option. zavesca is indicated for the treatment of the progressive neurological manifestations in adult and paediatric patients with niemann-pick type c disease.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - eliglustat tartrate - capsule - 84.4mg

Israel - English - Ministry of Health

sanofi israel ltd - eliglustat - hard capsule - eliglustat 84.4 mg - eliglustat - cerdelga is indicated for the long-term treatment of adult patients with gaucher disease type 1 (gd1), who are cyp2d6 poor metabolisers (pms), intermediate metabolisers (ims) or extensive metabolisers (ems).

Israel - English - Ministry of Health

mbi pharma ltd., israel - miglustat - hard capsule - miglustat 100 mg - miglustat - miglustat dipharma is indicated for the oral treatment of mild to moderate type i gaucher disease. miglustat dipharma may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable. miglustat dipharma is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with niemann-pick type c disease.

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

sanofi-aventis south africa (pty) ltd - injection - see ingredients - each 10,0 ml liquid contains imiglucerase 400,0 units

Israel - English - Ministry of Health

a.l. medi-market ltd. - miglustat - capsules - miglustat 100 mg - miglustat - miglustat g.l. is indicated for the oral treatment of mild to moderate type i gaucher disease. miglustat g.l. may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable. miglustat g.l. is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with niemann-pick type c disease.